MedTrace Logo

Anti-Restenosis After AMI by Erythropoietin

NCT00423020 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2007-01-17

No results posted yet for this study

Summary

The EPOC-AMI study is to assess the safety and the efficacy of systemic administration of erythropoietin for inhibition of neointimal hyperplasia after stent implantation in the patients with acute myocardial infarction

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

Erythropoietin

Sponsors & Collaborators

  • Kyoto Prefectural University of Medicine

    lead OTHER

Principal Investigators

  • Hiroaki Matsubara, M.D., Ph.D. · Kyoto Prefectural University of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00423020 on ClinicalTrials.gov